Activist investors filed Schedule 13D disclosures on five public companies between January and March, marking positions in Alkami Technology ($1.9B market cap), Smith & Nephew ($10.8B), Navigator Holdings ($1.1B), Diebold Nixdorf ($780M), and Kymera Therapeutics ($1.4B). The filings arrived without coordination, but the sector dispersion—enterprise software, orthopedic devices, LPG shipping, ATM infrastructure, and precision medicine—suggests activists are hunting neglected names with operational torque rather than chasing thematic concentration.
Alkami, a cloud banking platform serving 200+ U.S. regional banks, drew activist interest after gross margins compressed 320 basis points year-over-year to 54.1% in Q4 2024, despite revenue growing 24%. The 13D filer acquired a stake north of 5% and has not yet publicly outlined demands, though the company's $87M annual R&D spend against $312M trailing revenue invites scrutiny. Smith & Nephew, the British orthopedic and wound-care manufacturer, saw an activist take a position following 18 months of flat operating margins and a 12% underperformance versus the MSCI World Health Care Index. Navigator Holdings, which operates 38 liquefied gas carriers, attracted attention after its $41M net income in 2024 translated to a price-to-earnings ratio of 7.2x—half the peer median. Diebold Nixdorf, emerging from a prepackaged Chapter 11 in 2023, remains a restructuring story with $1.1B in remaining debt. Kymera Therapeutics, a degrader-focused biotech with no marketed products, has burned $310M in cash over the past 24 months and trades at 1.8x book value, making it a potential repositioning candidate or acquisition target.
The clustering matters less for the individual names than for the implicit signal: activists are no longer waiting for macro clarity. The five targets share characteristics—depressed valuations relative to sector comps, recent margin deterioration or restructuring overhang, and market caps under $2B where a 5-10% position affords genuine influence. The spread across industries also suggests activists are running sector-agnostic screens for operational inefficiency rather than riding tailwinds. When activism disperses this widely in a single quarter, it typically precedes either a wave of M&A (as underperformers get repriced via board pressure) or a series of asset sales and spinoffs. Both outcomes tend to surface within 12-18 months of the initial 13D.
Operators and allocators should track three follow-on events. First, whether any of the five activists file additional 13D amendments within 60 days, signaling intensified accumulation or board engagement. Second, whether Alkami or Smith & Nephew announce operational reviews or margin-improvement programs in their next earnings calls (May for Alkami, late April for Smith & Nephew). Third, whether Navigator Holdings or Kymera draw additional activist or strategic interest—both have the valuation profile and sector positioning to attract competing bids if one activist opens the door.
Diebold Nixdorf trades at 0.4x sales. The company expects $2.9B in revenue for 2025. That's a $1.16B enterprise value for a global ATM and point-of-sale footprint.